Invention Grant
- Patent Title: Compounds inhibiting leucine-rich repeat kinase enzyme activity
- Patent Title (中): 抑制富含亮氨酸的重复激酶活性的化合物
-
Application No.: US14772290Application Date: 2014-02-27
-
Publication No.: US09416126B2Publication Date: 2016-08-16
- Inventor: Michael Miller , Kallol Basu , Duane DeMong , Jack Scott , Wei Li , Joel Harris , Andrew Stamford , Marc Poirier , Paul Tempest
- Applicant: Merck Sharp & Dohme Corp.
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Keith D. MacMillan; John C. Todaro
- Priority: WOPCT/CN2013/072128 20130304
- International Application: PCT/US2014/018876 WO 20140227
- International Announcement: WO2014/137719 WO 20140912
- Main IPC: A61K31/505
- IPC: A61K31/505 ; C07D403/14 ; C07D401/14 ; C07D405/14 ; C07D413/14 ; C07D409/14 ; C07D417/14 ; A61K31/506 ; C07D471/10 ; C07D491/107 ; C07D498/08 ; C07D403/04
Abstract:
The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.
Public/Granted literature
- US20160009696A1 COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY Public/Granted day:2016-01-14
Information query
